Table 1.

Clinical studies included in the efficacy versus voriconazole plasma concentration analysis

Indicationa	No. of patients (% success)	Voriconazole doseb	Maximum duration of therapy (wks)	Reference
Chronic IFIs in non-neutropenic patients	52 (60)	p.o., 200 mg q12h*	24	32
Invasive aspergillosis	110 (63)	i.v., 6 mg/kg ×2 q12h → 3 mg/kg q12h; p.o., 200 mg q12h*	24	9
Esophageal candidiasis in AIDS	185 (76)	p.o., 200 mg q12h	6	1
Invasive aspergillosisa	166 (63)	i.v., 6 mg/kg ×2 q12h → 4 mg/kg q12h; p.o., 200 mg q12h*	12	14
Empirical therapyc	13 (46)	i.v., 6 mg/kg ×2 q12h → 3 mg/kg q12h; p.o., 200 mg q12h*	12	44
Invasive fungal infectionsd	313 (51)	i.v., 6 mg/kg ×2 q12h → 4 mg/kg q12h; p.o., 200 mg q12h*	12	26
Non-neutropenic candidemia	252 (75)	i.v., 6 mg/kg ×2 q12h → 4 mg/kg q12h; p.o., 200 mg q12h*	8	21

^aTwo separate studies.

^b*, Dose escalation allowed. p.o., peroral; i.v., intravenous; q12h, every 12 h; ×2, administered twice.

^cOnly patients with data review committee-determined baseline infections were included.

^dSalvage therapy, intolerance, no approved therapy.